Filtered By:
Cancer: Skin Cancer
Infectious Disease: Pandemics
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 507 results found since Jan 2013.
Integrated digital pathology at scale: A solution for clinical diagnostics and cancer research at a large academic medical center
ConclusionsWe highlight major challenges and lessons learned when going digital to provide orientation for other pathologists. Building interconnected solutions will not only increase adoption of DP, but also facilitate next-generation computational pathology at scale for enhanced cancer research.
Source: Journal of the American Medical Informatics Association - July 14, 2021 Category: Information Technology Source Type: research
NCCN Panel: Defer Nonurgent Skin Cancer Care During Pandemic NCCN Panel: Defer Nonurgent Skin Cancer Care During Pandemic
The National Comprehensive Cancer Network says instead opt for treatment with checkpoint or BRAF/MEK inhibitors, except when metastatic nodes are threatening vital structures.Medscape Medical News
Source: Medscape Medical News Headlines - April 9, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Cochrane Lifetime and Emeritus Members
Cochrane is proud to announce new lifetime and emeritus memberships,recognizing the extraordinary contributions of individuals who have made an exceptional, long-standing contribution to Cochrane ’s work and leadership.Cochrane ' s strength is in its collaborative, global community. Over the last 30 years, our members and supporters from more than 130 countries have worked together to produce credible, accessible health information and help inform health decision-making. Though we are spread out across the globe, our shared passion for health evidence unites us.Cochrane ’s Membership schemehelps reward everyone who hel...
Source: Cochrane News and Events - May 3, 2023 Category: Information Technology Authors: Muriah Umoquit Source Type: news
Abstracts of Presentations at the Association of Clinical Scientists 143 < sup > rd < /sup > Meeting Louisville, KY May 11-14,2022
Conclusion: These assays are suitable for routine diagnostic. The UltraFast NextGenPCR is the fastest with average time (30mins), followed by Agilent (2 hrs) and MassArray (6hrs). Upon completion of this activity, participants should be able to examine, measure and compare results from different assays for SARS detection, evaluate and diagnose accurately, as well as being able to plan, organize and recommend a diagnostic procedure for diagnostic laboratory. Key words: SARS-CoV-2, RNA extraction, RT-PCR, limit of detection, quantification cycle, COVID-19, in vitro diagnostic tests, Agilent, Massarray, Ultrafast. [20] From t...
Source: Annals of Clinical and Laboratory Science - July 1, 2022 Category: Laboratory Medicine Source Type: research
From “Serum Sickness” to “Xenosialitis”: Past, Present, and Future Significance of the Non-human Sialic Acid Neu5Gc
Conclusions and Perspectives
In this review, we have discussed important milestones from the early description of “Serum-sickness” as being due to antibodies directed against Neu5Gc epitopes all the way to the present-day therapeutic implications of these antibodies in cancer therapy. Some of these milestones have been represented in a concise timeline (Figure 6). While the “Xenosialitis” hypothesis is well-supported in the human-like mouse models, it has yet to be conclusively proven in humans. It remains to be seen if “Xenosialitis” plays a role in other uniquely-human dis...
Source: Frontiers in Immunology - April 16, 2019 Category: Allergy & Immunology Source Type: research
Ad hoc announcement pursuant to Art. 53 LR Roche records solid results for the first nine months of 2022
Basel, 18 October 2022Group salesup 2%1 at constant exchange rates (CER) and 1% in Swiss francs; as expected, significantly lower COVID-19-related sales in both divisions in the third quarterSales in the Pharmaceuticals Divisionat the previous year ’s level with significantly lower sales of COVID-19-related products (Ronapreve and Actemra/RoActemra) and losses to biosimilars, offset by strong growth of newer medicinesSales in the Diagnostics Divisionrise 6%; base business remains strong; as expected, demand for COVID-19 tests sharply down in third quarterHighlights in the third quarter:EU approval forVabysmo (severe eye ...
Source: Roche Media News - October 18, 2022 Category: Pharmaceuticals Source Type: news
